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We previously identified Hop as over expressed in invasive pancreatic cancer cell lines and
malignant tissues of pancreatic cancer patients, suggesting an important role for Hop in
the biology of invasive pancreatic cancer. Hop is a co-chaperone protein that binds to both
Hsp70/Hsp90.Wehypothesised that by targetingHop, signallingpathwaysmodulating inva-
sion and client protein stabilisation involving Hsp90-dependent complexes may be altered.
In this study, we show that Hop knockdown by small interfering (si)RNA reduces the inva-
sion of pancreatic cancer cells, resulting in decreased expression of the downstream target
gene, matrix metalloproteinases-2 (MMP-2). Hop in conditioned media co-immunoprecipi-
tates with MMP-2, implicating a possible extracellular function for Hop. Knockdown of Hop
expression also reduced expression levels of Hsp90 client proteins, HER2, Bcr-Abl, c-MET and
v-Src. Furthermore, Hop is strongly expressed in high grade PanINs compared to lower PanIN
grades, displaying differential localisation in invasive ductal pancreatic cancer, indicating
that the localisation of Hop is an important factor in pancreatic tumours.
Our data suggests that the attenuation of Hop expression inactivates key signal transduc-
tion proteins which may decrease the invasiveness of pancreatic cancer cells possibly
through the modulation of Hsp90 activity. Therefore, targeting Hop in pancreatic cancer
may constitute a viable strategy for targeted cancer therapy.
 2011 Elsevier Ireland Ltd. All rights reserved.1. Introduction survival rate is between 1% and 4% [1], mainly due toPancreatic adenocarcinoma is one of the most lethal
and poorly understood human malignancies. The 5-yearand Ltd. All rights reserved.
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Vincent’s Universitythe lack of effective therapies. Conventional treatment
used to treat pancreatic cancer such as surgery, chemo-
therapy, radiation or combinations of these have had
very little effect on the overall survival of this disease
[2].
Hop (Hsp70/Hsp90-organising protein) or STIP1
(stress-induced phosphoprotein 1) mediates the associa-
tion, and forms a physical complex with the molecular
chaperones heat shock proteins (Hsp) Hsp70 and Hsp90
[3,4] which is dependent on the hydrolysis of ATP and
ADP/ATP exchange. Hop optimises the functional co-
operation between Hsp70 and Hsp90 which requires
highly co-ordinated interactions for the folding and con-
formational regulation of a variety of proteins [5]. The
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is involved in the folding and maturation of key regula-
tory proteins involved in cell viability [6], such as steroid
hormone receptors, transcription factors and kinases
(some of which are involved in cancer progression).
The role of Hop in tumour progression is not fully eluci-
dated; however, Hop has been shown to be over ex-
pressed in colonic carcinoma cells [7] and in
hepatocellular carcinoma (HCC) [8]. Hop is secreted by
and shown to induce proliferation in glioma tumour cells
through MAPK and P13K pathways [9]. Hop has also
been implicated in the controlled death process. Brede-
meyer et al. [10] confirmed Hop as a substrate of the
apoptotic protease granzyme B (GzmB), as Hop was di-
rectly cleaved by GzmB in vitro and in cells undergoing
GzmB-induced apoptosis. Expression of the two cleavage
fragments of Hop did not induce cell death; however,
cleavage of Hop by GzmB did result in loss of Hop func-
tion in vitro.
There is increasing evidence that heat shock proteins
play an important role in the development, maintenance
and progression of cancer [11]. Heat shock proteins such
as, Hsp90 and Hsp70 have previously been implicated in
pancreatic cancer [12,13]. Hsps are highly conserved mol-
ecules, which protect cells from various environmental
damages, including stress and carcinogenesis [14] and are
activated by the ubiquitin–proteasome pathway. The cova-
lent attachment of ubiquitin to protein regulates a number
of cellular processes including responses to stress. This
process is responsible for selective targeting of proteins
for degradation. The induced Hsps play roles as cellular
chaperones, and many modulate apoptotic pathways, par-
ticularly those involving mitochondria, conferring protec-
tion from stressful stimuli including chemotherapeutic
agents [15]. Hsp90 client proteins include mutated p53,
Bcr-Abl, Raf-1, Akt, HER2 (ErbB2) and hypoxia inducible
factor-1alpha (HIF-1alpha) [16].
We previously profiled Hop expression in an in vitro
pancreatic cancer cell line invasion model and pancreatic
tumour tissue specimens [17]. In the present study, we
hypothesised that modulation of Hop expression could al-
ter invasion and affect the activity of Hsp90 and its client
proteins; suppression of Hop by siRNA reduced invasion
through decreased expression of MMP-2. We further show
that modulation of Hop alters the activities of representa-
tive Hsp90 client proteins HER2, Bcr-Abl, c-MET and v-Src.
This study reports that Hop is likely to play a role in inva-
sion of pancreatic cancer cells, and possibly contribute to
the highly aggressive metastatic phenotype of pancreatic
cancer. In addition our findings support Hop as a potential
therapeutic target for the treatment of pancreatic cancer.2. Materials and methods
2.1. Cell lines
The human pancreatic cell lines Panc-1, SW1990, Ca-
pan-1, MiaPaCa-2 (ATCC, USA), HPAC (DSMZ, Germany)
and BxPc-3 (ECACC, UK) were used in this study. Clone
#3 and Clone #8 were previously isolated by single celldilution from MiaPaCa-2 in this laboratory [18]. Cells were
maintained in a humidified atmosphere containing 5% CO2
at 37 C in Dulbecco’s modified Eagles medium (DMEM)
supplemented with 5% (v/v) fetal bovine serum (Sigma–Al-
drich). All cell lines were free from Mycoplasma as tested
with the indirect Hoechst staining method.
2.2. Invasion assays
Invasion assays were performed as previously described
[19]. Briefly, matrigel was diluted to 1 mg/ml in serum-free
DMEM. 100 ll of matrigel was coated on each Boyden
chamber insert (Falcon) (8.0 lm pore size), in a 24-well
plate (Costar) and incubated overnight at 4 C. The matri-
gel was allowed polymerise at 37 C for 1 h, then washed
with DMEM. 100 ll of complete DMEM was added to the
wells and 1  105/100 ll cells were then seeded onto the
insert. An aliquot of 500 ll of complete DMEM was added
into the underside of the well. After 24 h incubation, the
inside of the insert was wiped with a wet cotton swab.
The under surface was gently rinsed with PBS and stained
with 0.25% (w/v) crystal violet for 10 min, rinsed again
with sterile water and allowed to dry. The inserts were
then viewed under the microscope and the number of cells
per field in 10 random fields, were counted at 200 mag-
nification. The average number of cells per field was then
multiplied by a factor of 140 (growth area of membrane/
field area viewed at 200magnification (calibrated using
a microscope graticule)) to determine the total number of
invading cells. Experiments were performed in triplicate.
2.3. Immunoblotting
Whole protein was extracted from cell lysates using 1
lysis buffer (50 mM Tris–Cl, 150 mM NaCl, and 0.5% (v/v)
NP-40). Lysates were centrifuged for 15 min at 16,000g at
4 C. Protein concentrations were determined using the
Bio-Rad Bradford protein assay according to manufac-
turer’s instructions (Bio-Rad). A concentration of 25 lg of
protein was separated by 7.5 and 10% (w/v) SDS–PAGE gels
under reducing conditions. Proteins were transferred to
nitrocellulose membrane (Amersham). Membranes were
blocked at 4 C overnight in TBS (25 mM Tris–HCl, pH 7.4,
150 mM NaCl, 2.7 mM KCl) containing 5% (w/v) lowfat
milk powder. Membranes were probed with antibodies
Hop/STIP1 (ab56873, Abcam), Hsp70, Hsp90 (#4872,
#4875, Cell Signaling), Bcr-Abl (#2862, Cell Signaling),
HER2 (#2165, Cell Signaling), c-MET (sc-10, Santa Cruz),
v-Src (OP07T, Merck) and b-actin (Sigma). Membranes
were washed 3 for 5 min with PBS-Tween-20 (0.5% v/v)
and incubated with secondary antibodies, anti-mouse (Sig-
ma) and anti-rabbit (Cell Signaling) for 1 h at RT and wash-
ing step repeated. Detection was performed with Luminol
reagent (Santa Cruz Biotechnology).
2.4. siRNA transient transfections
Three pre-designed siRNAs (Ambion) were chosen for
each of the protein/gene targets and transfected into cells.
Hop/STIP1 siRNA targets (Ambion, #106197, #106196, and
#106195). For each set of siRNA transfections carried out, a
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# 17010) were used. siRNA experiments were set up using
2 ll NeoFx (Ambion, AM4511), to transfect 30 nM siRNA at
a cell density of 3  105/ml in a 6-well plate. Transfection
medium was removed after 24 h and replaced with fresh
growth medium. The transfected cells were collected at
72 and 96 h for immunoblotting and assayed for changes
in invasion capacity at 72 h using the in vitro invasion as-
say (as previously described).
2.5. Zymography
Pancreatic cancer cells (70–80% confluent) were
washed and replenished with serum-free DMEM for
48 h. Cells were then pretreated with various concentra-
tions of 17-AAG (Merck) for 24 h vs control conditioned
media in serum-free conditions for 72 h. The volume of
conditioned medium was normalised by cell number.
CM samples were denatured, run on 10% (w/v) gelatin
gels (Invitrogen Life Technologies) and renatured in
zymogram renaturing buffer and developed in zymogram
developing buffer (Invitrogen). Gels were stained with
0.5% (w/v) coomassie blue, destained in a solution con-
taining 10% (v/v) methanol and 7.5% (v/v) acetic acid.
Zones of gelatinolytic activity were detected as clear
bands against a blue background.
2.6. Immunoprecipitation (IP)
Protein from conditioned media was lysed in buffer
(4% w/v CHAPS, 7 M urea, 2 M thiourea, 10 mM Tris–
HCl, 5 mM magnesium acetate pH 8.5) and incubated
with 200 lg of Hop (sc-136082, Santa Cruz) or control
mouse IgG, at 4 C, shaking, for 30 min. In order to pre-
cipitate the antibody/antigen complex, 50 ll of packed
Protein-L agarose beads (#20512, Pierce) were added
and samples incubated overnight on a rocking platform
at 4 C. Samples were then centrifuged at 16,000g for
25 s and pellets washed with IP wash buffer 3. Samples
were centrifuged gently after each wash step. Superna-
tants were removed and pellets resuspended in 50 ll
denaturing buffer and boiled at 95 C for 5 min. Dena-
tured samples were then centrifuged at 16,000g for
3 min and supernatant collected and stored at 20 C.
Immunoprecipitates were separated on 7.5% (w/v) SDS
PAGE gels and probed with Hsp90 (#4875, Cell Signal-
ing), Hop/STIP1 (ab56873, Abcam) and MMP-2 (IM53,
Merck) antibodies.
2.7. Immunohistochemistry
Formalin-fixed paraffin-embedded pancreatic tumour
4-lm sections of tissue blocks were cut using a micro-
tome, mounted onto poly-l-lysine coated slides and dried
overnight at 37 C. Slides were stored at room tempera-
ture until required. Briefly, the slides were immunohisto-
chemically stained using primary antibodies specific for
Hop/STIP1 (ab56873, Abcam). After deparaffinisation
and rehydration, the slides were subjected to an antigen
retrieval step consisting of 20-min incubation in pH 9.0
buffer (Target Retrieval, Dako) in a 95 C water bathfollowed by cooling to room temperature. Staining was
performed using an automated staining apparatus for
IHC (Autostainer, Dako) according to the manufacturer’s
guidelines. The proper positive and negative controls
were processed at the same time. The slides were coun-
terstained with haematoxylin, dehydrated in graded alco-
hols and mounted (DPX, Sigma). Scoring and
interpretation was carried out by consultant pathologist
NS.
2.8. Statistical analysis
Student’s t-tests (two-tailed, two-sample unequal vari-
ance) were used to analyse differences in protein expres-
sion between comparisons. A p-value 60.05, 60.01 and
60.005 was considered statistically significant.
3. Results
3.1. Hop is associated with invasive pancreatic carcinoma
We previously identified Hop/STIP1 by 2D DIGE followed by MALDI-
TOF MS as 2-fold more abundant in Clone #3, a highly invasive sub-pop-
ulation of the human pancreatic cancer cell line MiaPaCa-2, compared to
the low invasive Clone #8 [17]. In this study, we examined constitutive
Hop expression in a panel of seven human pancreatic cancer cell lines
by Western immunoblot (Fig. 1A) and studied its expression with the
invasive status of the cell lines (Fig. 1B and C). All cell lines express
Hop but higher abundance of Hop was observed in the more invasive cell
lines.
3.2. Hop, as a novel inducer of pancreatic cancer cell invasion
To determine whether loss of Hop affects the ability of cells to invade
in vitro, we compared the ability of BxPc-3 and Panc-1 (high Hop expres-
sion) human pancreatic cancer cell lines to invade through matrigel-
coated Boyden chambers post Hop-siRNA transfection. As Hop-siRNA
(2) and (3) were more effective at Hop knockdown (Fig. 5), we used these
siRNAs for further studies. Invasion of Panc-1 cells was reduced by 50%
(p = 0.0005) using Hop-siRNA (2) and by 50% (p = 0.003) with Hop-siRNA
(3) (Fig. 2A). Invasion of BxPc-3 transfected cells were reduced by 51%
(p = 0.002) using Hop-siRNA (2) and by 46% (p = 0.002) in the case of
Hop-siRNA (3) (Fig. 2B).
3.3. Matrix metalloproteinases down regulated as a result of Hop knockdown
We further investigated how knockdown of Hop using siRNA could af-
fect invasion. Previously, secretion of HSP90a into the extracellular ma-
trix surrounding tumour cells was reported to assist the activation of
MMP-2 as well as contributing to tumour cell invasiveness [20,21]. We
show that Hop is found in the conditioned medium of both Panc-1 and
BxPc-3 cells and therefore may possibly have an extracellular role in
Hsp90 client protein activation (Fig. 3A). Inhibition of Hop by Hop-siRNA
transfection reduced the expression of MMP-2 in both Panc-1 and BxPc-3
as determined by immunoblotting (Fig. 3B).
3.4. Hop co-immunoprecipitates with MMP-2
Our findings suggest that Hop may act as an extracellular protein;
we confirmed that Hop co-immunoprecipitates with MMP-2 in BxPc-3
conditioned media, showing a direct interaction between these proteins
(Fig. 4A), suggesting that Hop may be acting as an extracellular co-
chaperone to Hsp90, in turn activating MMP-2. Our studies support
this suggestion as Hop, p23 and Hsp90 were found in the conditioned
media of HT-1080 cells, showing a direct interaction between these
proteins extracellularly [21]. Inhibition of Hop may have affected
MMP-2 expression and activity through altering the activity of extra-
cellular Hsp90. A study by Tsutsumi et al. [22] using the non cell-per-
meable Hsp90 inhibitor, DMAG-N-oxide, reduced in vitro tumour cell
Fig. 1. Hop protein expression in human pancreatic cancer cells. (A) Representative Western immunoblot showing the expression of constitutive Hop in a
panel of pancreatic cancer cell lines. Housekeeping gene b-actin was used as an internal control. (B) Densitometry analysis of Hop bands (normalised to b-
actin). Error bars represent the standard deviation of triplicate experiments. (C) The invasive capacity of panel of cell lines. The total number of invading
cells was determined by counting the number of cells per field in 10 random fields, at 200magnification. The average number of cells per field was then
multiplied by a factor of 140 (growth area of membrane/field area viewed at 200magnification (calibrated using a microscope graticule)). Error bars
represent the standard deviation of triplicate invasion assay experiments (n = 3).
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in vivo. The monoclonal antibody (mAb) directed against Hsp90, mAb
4C5, inhibited melanoma cell invasion and significantly reduced metas-
tasis in vivo by binding to surface Hsp90 as it is not internalised, fur-
ther indicating an extracellular role for Hsp90 [23]. We also show
that the specific Hsp90 inhibitor, geldanamycin (17-AAG) at 0.1 lM
and 1 lM blocks MMP-2 and MMP-9 [24] activation as revealed by
zymography (Fig. 4B). Invasion in the highly invasive Panc-1 and
BxPc-3 cells lines was also reduced at 1 lM 17-AAG (Fig. 4C and D),
proliferation and cell survival at this concentration was not effected
(data not shown).3.5. Role of Hop as an Hsp90/Hsp70 co-chaperone protein – silencing of Hop
alters expression of downstream Hsp90 client proteins
Hsp90 client proteins play important roles in the regulation of the
cell cycle, cell growth, cell survival, apoptosis, and tumour progres-
sion. To investigate whether Hop could serve as a therapeutic target
in pancreatic cancer, we used Hop-siRNA to knockdown Hop expres-
sion in three invasive human pancreatic cancer cell lines: Clone #3,
BxPc-3 and Panc-1. 72 h post Hop-siRNA transfection, Hop expression
was reduced in Clone #3, BxPc-3 and Panc-1 (Fig. 5). Hop-siRNA did
not alter levels of Hsp70 or Hsp90 expression in BxPc-3, Panc-1 and
Fig. 2. Knockdown of Hop reduces the invasion of Panc-1 and BxPc-3 cells. A. Panc-1 and B. BxPc-3 cells were transfected with non-targeting scrambled
siRNA (control siRNA) and two independent siRNA sequences against Hop. The total number of invading cells was determined by counting the number of
cells per field in 10 random fields, at 200magnification. The average number of cells per field was then multiplied by a factor of 140 (growth area of
membrane/field area viewed at 200magnification (calibrated using a microscope graticule)). Error bars represent the standard deviation of triplicate
invasion assay experiments (n = 3).
Fig. 3. Hop as an extracellular protein can disrupt MMP-2 expression. (A) Serum-free conditioned media from Panc-1 and BxPc-3 cells was collected,
concentrated and immunoblotted for Hop. (B) Panc-1 and BxPc-3 cells transfected with Hop-siRNA (2) and (3) were immunoblotted for MMP-2.
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teins, HER2, Bcr-Abl, c-MET and v-Src were reduced with Hop-siRNA
transfection (Fig. 5). These results suggest that the effect of Hop
knockdown in pancreatic cancer may be mediated through these
proteins.3.6. Localisation of Hop membrane staining in pancreatic cancer tumours
In a small panel of pancreatic tumours we identified cytoplasmic
Hop expression in areas of tumour invasion and in necrotic cells in
the epithelium of paraffin-embedded pancreatic tumour specimens.
Fig. 4. Hop co-immunoprecipitates with Hsp90 and MMP-2. (A) Hop was immunoprecipitated from BxPc-3 conditioned media as described in materials
and methods. Proteins were detected by MMP-2 and Hsp90 antibodies as indicated (right side of panel). (B) Effect of 17-AAG on pancreatic cancer. To
validate Hop as an inhibitor of invasion in the Hsp90-complex, we used the Hsp90 pharmacological inhibitor 17-AAG and observed its effect on MMP-2 and
MMP-9 expression. BxPc-3 cells were treated with 0.1 lM and 1 lM of 17-AAG for 24hrs under serum-free conditions. Conditioned medium was collected
and MMP-2 and MMP-9 activities were analysed by gelatin zymography. (C) Representative invasion assay pictures of cells invaded through Boyden
invasion chambers (8 lm pore size) coated with matrigel basement membrane matrix stained with 0.25% (w/v) crystal violet under control conditions and
24 h treatment with 1 lM 17-AAG in Panc-1 and BxPc-3 cells. Magnification 200, scale bar 200 lm. (D) Invasion potential of Panc-1 and BxPc-3 cells
treated with 1 lM 17-AAG as outlined in materials and methods. Graphs represented as the total number of invading cells, as determined by counting the
number of cells per field in 10 random fields, at 200magnification. The average number of cells per field was then multiplied by a factor of 140 (growth
area of membrane/field area viewed at 200magnification (calibrated using a microscope graticule)). Values are mean ± standard deviation (n = 3).
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acinar cells of the exocrine pancreas but at a lesser intensity compared
to tumour [17]. To explore Hop as a potential target for invasive pan-
creatic cancer, we studied the profile of 17 pancreatic tumours, 15
invasive/metastatic pancreatic ductal adenocarcinomas (PDACs), 1 chol-
angiocarcinoma and 1 intraductal papillary mucinous neoplasm (IPMN).
All PDACs specimens displayed cytoplasmic Hop staining (Fig. 6A and
B); in general stronger Hop staining was observed in higher PanIN than
in lower PanIN grades. Fig. 6A shows strong Hop staining in PanINgrade 3 (arrow 1) compared to negligible staining in PanIN grade1
(arrow 2). The invasive front of the tumour also displayed strong
Hop staining as shown in Fig. 6B by perineural invasion. The nerve
(arrow 1) is infiltrated by invasive pancreatic cells with high Hop
expression (arrow 2). We also observed differential localised (sub-
nuclear and membrane) staining of Hop. In Fig. 6C, linear sub-nuclear
staining of Hop was seen in a PanIN grade1 tumour. Furthermore,
membrane localisation of Hop was observed in an invasive pancreatic
tumour with mucinous features (Fig. 6D).
Fig. 5. Effect of Hop knockdown by siRNA on Hsp90 client proteins in BxPc-3, Panc-1 and Clone #3. Pancreatic cancer cells were transfected with three
independent siRNAs against Hop and the scrambled control siRNA. A 72 h post transfection, the constitutive levels of Hop, Hsp90, Hsp70, HER2, Bcr-Abl, c-
MET and v-Src were assayed by Western immunoblot.
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Previously, protein identification by 2D DIGE followed
by MALDI-TOF MS established a 2-fold increase in Hop
expression in the more invasive pancreatic cancer cell line
Clone #3 compared to Clone #8 (low invasion) [17]. In this
study, we investigate the role of Hop in cancer cell invasion
and its potential as a therapeutic target; we firstly provide
evidence that Hop expression in pancreatic cancer cell
lines corresponds to their invasive abilities. We show that
Hop is involved in in vitro invasion in pancreatic cancer cell
lines possibly through interaction with MMP-2. To our
knowledge this is the first study implicating Hop in pan-
creatic cancer invasion via MMP-2. Eustace et al. [21]
showed that Hsp90a chaperone-complex interactions are
involved in MMP-2 activity and invasiveness in the fibro-
sarcoma cell line, HT-1080. Our work showed that loss of
Hop after siRNA transfection reduced the invasiveness of
BxPc-3 and Panc-1 cells; this decrease in invasion was
mediated by a reduction in MMP-2 expression. The degra-
dation of the extracellular matrix and connective tissue,leading to tumour invasion and metastasis, is facilitated
by MMPs [25]. MMPs are a family of proteinase enzymes
requiring a zinc ion at their active site. MMPs are secreted
extracellularly in a latent form and require activation for
proteolytic activity. They are inhibited by specific tissue
inhibitors of metalloproteinases (TIMPs) (reviewed in
[26]). Gress et al. [27,28] found that MMP-2 and MMP-9
may be involved in processes leading to the strong desmo-
plastic reaction - the deregulation of the extracellular ma-
trix, including degradation and accumulation of dense
fibrous tissue observed in pancreatic tumours. Hop was
found in the CM of BxPc-3 and Panc-1 suggesting that it
may interact with MMP-2 extracellularly, also defined in
other studies [21]. We showed further evidence for this
interaction as MMP-2 co-immunoprecipitated with Hop
in BxPc-3 CM. Hsp90 also co-immunoprecipitated with
Hop. Hsp90 expression in malignant cells has been
reported to be constitutive, and intracellular levels are 2–
10-fold higher compared to normal cells, suggesting a cru-
cial role in survival and growth of cancer cells [29]. Using
the specific Hsp90 inhibitor, 17-AAG, we confirmed that
Fig. 6. Differential localisation of Hop in invasive pancreatic tumours. (A) PanIN grade 3 (arrow 1) displaying strong cytoplasmic Hop staining compared to
PanIN grade 1 showing no Hop expression (arrow 2). (B) Perineural invasion in PDAC, cancer cells invading around the nerve (arrow 1) stained strongly for
Hop (arrow 2). (C) PanIN grade 1 PDAC displaying sub-nuclear accumulation of Hop. (D) Invasive mucinous tumour displaying strong Hop complete
membrane staining magnification 200.
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in MMP-2 and MMP-9 activation. This suggests a role for
Hop in Hsp90-mediated inhibition of invasion through
extracellular interactions. Hop acts as a co-chaperone in
the Hsp90 chaperone cycle stabilising and activating a
wide array of client proteins [30]. Having demonstrated
that Hop knockdown resulted in decreased invasion
through extracellular interaction with Hsp90 and MMP-2,
we investigated whether siRNA knockdown of Hop could
affect Hsp90-mediated client protein expression. Our
study showed that Hop-siRNA mediated a decrease in
levels of Hsp90 ‘client’ proteins; HER2, Bcr-Abl, c-MET and
v-Src in pancreatic cancer cell lines. However, an important
factor in the Hop-mediated Hsp90 inactivation could rely
on whether the two proteins are complexed in the tumour
cells. Kamal et al. [31] determined that Hsp90 in tumour
cells is present in multi-chaperone complexes and is en-
gaged in active chaperoning. Co-immunoprecipitation of
normal and tumour cell lysates with antibodies to Hsp90
revealed that more Hsp90 in tumour cells was present in
complexes with co-chaperone proteins such as p23 and
Hop compared to normal cells. Immunoprecipitation with
antibodies to both p23 and Hop showed that the entire tu-
mour cell pool of Hsp90 was present in complexes unlike
normal cells. These results suggest that Hsp90 in tumour
cells is in the form of multi-chaperone complexes whichare actively engaged in chaperoning client oncoproteins.
Therefore, Hop expression, through specific inhibition of
the Hsp90-Hop complexes, survival pathways and MMP
activation, could contribute to invasion in the pancreatic
cancer cell lines, therefore making it a potentially valuable
target for pancreatic cancer therapy.
We cannot exclude the possibility that alteration of the
Hsp90 pathway decreases invasion through interference
with oncogenic signalling pathways. MET, a receptor for
hepatoctye growth factor/scatter factor (HGF/SF) has been
previously shown to play an important role in cancer inva-
sion and metastasis [32]. As c-MET is a client of Hsp90, it is
destabilised by the Hsp90 inhibitor, 17-AAG, which blocks
reactivation of downstream signalling pathways (Akt Erk
and/or STAT3) and EGFR family members [33]. Webb
et al. [34] showed that geldanamycin (GA) down regulates
MET expression at nanamolar concentrations, thus inhibit-
ing HGF/SF-mediated cell motility and invasion. Another
Hsp90 client protein, HER2 has been proposed to interact
extracellularly with Hsp90 – activating HER2 by heterodi-
merisation with HER3, leading to actin remodelling and
cell motility via activation of signal transduction pathways
MAPK and PI3 K-Akt [35,36].
The localisation of Hop in pancreatic cancer tumours
and its secretion by cell lines may be of importance,
as shown in other studies [21,37,9]. The mechanism of
188 N. Walsh et al. / Cancer Letters 306 (2011) 180–189secreted Hop is poorly understood. Hop is secreted from
fibrosarcoma cells [21] and from primary astrocyte cul-
tures [9,37]. Although Hop has been previously detected
in the Golgi apparatus and small vesicles [38]; no trans-
membrane/signal peptide is contained within the Hop
sequence. Therefore secretion of Hop may be through
non-classical secretory routes or through its membrane
interactions with prion proteins [39]. To exclude the
possibility of Hop expression in the media due to cell lysis
at a low rate, recombinant Hop could be used to mimic
extracellular secreted Hop and assess its function extracel-
lularly. There is evidence to suggest that localisation of
Hop may be due to phosphorylation. Hop can be phosphor-
ylated by cell cycle kinases, phosphorylation by cdc2 (cell
division cycle 2) kinase promotes cytoplasmic retention,
whereas phosphorylation by casein kinase II (CKII) pro-
motes nuclear Hop, suggesting that Hop might move
between the cytoplasm and the nucleus under certain cell
cycle conditions [40,41]. The nuclear accumulation of
Hop is primarily stress regulated and CKII phosphorylation
has been shown not to disrupt Hop-Hsp90 binding [36].
Longshaw et al. [42] reported that in the absence of Hop,
soluble pYStat3 levels are decreased and accumulation of
Stat3 occurs outside the nucleus in mESCs, suggesting that
Hop facilitates phosphorylation and transport of Stat3 into
the mESCs nucleus.
Immunohistochemical analysis revealed a correlation
between Hop expression and the degree of differentiation
in PDAC tumours. The PanIN lesions show sequential
changes in Hop expression levels from strong staining in
high PanIN grades and invasive carcinoma compared to
weak Hop staining in low PanIN grades. Differential Hop
expression occurs at different stages of the malignant pro-
gression of PDAC, suggesting a progressive increase in
expression as the tumour becomes more malignant, possi-
bly due to localisation of Hop resulting in nuclear/cytoplas-
mic or membrane accumulation of the protein.
In summary, we have demonstrated for the first time
that siRNAs specifically targeting human Hop substan-
tially reduced the invasion of human pancreatic cancer
cells in vitro through extracellular interactions with
MMP-2 and Hsp90. Decreasing Hop levels by siRNA also
degraded Hsp90 client proteins, HER2, Bcr-Abl, c-MET
and v-Src possibly through Hsp90 inactivation. Targeting
the Hsp90 pathway through Hop is an attractive strategy
as multiple oncoproteins are dependent on this chaper-
one activity. Our results suggest that disruption of the
Hop-Hsp90 complex may provide a novel mechanism
for Hsp90 dependent pathways in pancreatic cancer. Re-
cently, Horibe et al. [43] designed a novel peptide which
disrupts the interaction between Hsp90 and the TPR2A
binding domain of Hop. This specific inhibitor of
Hsp90-Hop interaction showed selective antitumour
activity, discriminating between normal and cancerous
cell lines. Cells treated with the inhibitor exhibited loss
of Hsp90-client proteins, survivin, CDK4 and Akt. Antitu-
mour activity was also observed in vivo in a xenograft
model of human pancreatic cancer in mice.
The differential localisation of Hop in invasive pancre-
atic tumours is interesting and further work into the signif-
icance of this observation is required in a larger panel ofpancreatic cancer specimens and additional confocal anal-
ysis in cell lines.Conflict of interest statement
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